KROS
Keros Therapeutics, Inc.
$12.07
+3.69%
2026-05-08
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Key Fundamentals
P/E Ratio
5.00
Forward P/E
-2.27
EPS (TTM)
$2.30
ROE
19.9%
Revenue Growth (YoY)
-87.3%
Profit Margin
35.7%
Debt/Equity
5.57
Price/Book
0.74
Beta
0.95
Market Cap
$227.8M
Avg Volume (10D)
282K
Recent Breakout Signals
No recent breakout signals detected for KROS.
Recent Price Range (60 Days)
60D High
$17.17
60D Low
$10.41
Avg Volume
405K
Latest Close
$12.07
Get breakout alerts for KROS
Sign up for Breakout Scanner to receive daily notifications when KROS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Keros Therapeutics, Inc. (KROS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KROS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KROS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.